In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Eisai Co., Ltd.

Potential For Califf’s Second Term As US FDA Commissioner Surprises, Excites Stakeholders

Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.

FDA Leadership

MedPAC’s Part B Options Include ‘Value-Based’ Payment During Accelerated Approval

Medicare Payment Advisory Commission also considering reviving least costly alternative policy in some way, but remains relatively hesitant about changes to ASP+6%.

Medicare Reimbursement

Health And Wellness Industry: IFF CEO Leaving, Abbott/Real Madrid Score Partnership, More

International Flavors & Fragrances looks for CEO to replace Andreas Fibig; Ultrahuman Healthcare appoints private equity expert as business chief; prebiotics developer Clasado taps nutritional scientist; Abbott kicks off nutritional partnership with Real Madrid; and CRN adjusts membership fees.

Commercial Executive Changes

Gilead’s First-In-Class Drug For Aggressive Breast Cancer On Track For EU Approval

EU reviewers have recommended five new medicines and a pneumococcal vaccine for EU-wide approval. New uses of several approved medicines have also drawn the thumbs up, while the sponsor of a cancer drug has withdrawn its product from the review process.

Approvals Drug Review
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • EA Pharma Co., Ltd.
    • Eisai China Inc
    • Eisai Laboratorios
    • Eisai Mexico
    • Eisai Participacoes Ltda. (Brazil Subsidiary)
    • H3 Biomedicine
    • HI-Eisai Pharmaceutical Inc.
    • Jingyi Weixiang (Shanghai) Health Industry Development Limited
    • Liaoning TianYi Biological Pharmaceutical Co., Ltd.
    • KAN Research Institute, Inc.
    • MGI Pharma, Inc.
    • Morphotek, Inc.
    • Zycos Inc.
    • Eisai Vietnam Co., Ltd.
UsernamePublicRestriction

Register